1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

New Meso Foundation Patient Services Director Joins Team

Dear friends and supporters,

We are delighted to report that the Meso Foundation has selected a Patient Services Director to succeed Mary Hesdorffer, who is retiring at the end of this month. After a nationwide search for an on-staff expert to help our patients navigate their diagnosis and treatment, support patients and their loved ones, and to ensure that we continue to be a valuable resource on mesothelioma to the entire community, we are excited to announce that Shannon Sinclair, RN, BSN, OCN, has joined our staff. Since last week, Shannon and Mary have been working closely together to transition patients and to connect with the medical community. After Mary’s retirement on October 31, 2021, Shannon will be your primary point of contact for patient needs.

Shannon is an experienced oncology nurse who has worked in a busy oncology center, served as an oncology clinical nurse educator for a major pharmaceutical company, and has worked with a specialty oncology pharmacy advising medical professionals and supporting patients. Shannon is an Oncology Certified Nurse (OCN) and has additional certifications in chemotherapy, biotherapy, and immunotherapy. She lives in Ohio on a small farm populated with rescued animals and loves to spend time outdoors with her family.  

Join me in welcoming Shannon to our team and the mesothelioma community! Feel free to connect with her via email at [email protected], by phone at (703) 879-3821, or on Facebook.

Julie Powers
Executive Director
Mesothelioma Applied Research Foundation

Also...

In Other News

Clinical Trials

Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different

Read More »

Peritoneal Surgery/HIPEC

Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC).  This session

Read More »

Share:

Facebook
Twitter
LinkedIn